Current Edition

News

CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again

In-person visitor numbers rebound sharply, with record C-Suite attendance and the largest-ever online presence.     The global pharma industry was out in full force …

Continue Reading →
News

LEO Pharma reveal positive results from delgocitinib research

Phase 3 clinical trial focuses on adults with moderate-to-severe chronic hand eczema. LEO Pharma has announced positive results from its DELTA 1 trial – the …

Continue Reading →
News

Spago Nanomedical begins endometriosis study

The clinical trial has received regulatory approval and involves endometriosis candidate SN132D. Spago Nanomedical has announced that it has received regulatory approval to initiate a …

Continue Reading →
News

Valneva shares positive chikungunya vaccine results

99% of participants retained very high neutralising antibody levels 12 months after treatment. Valneva has announced positive antibody persistence data twelve months for its chikungunya …

Continue Reading →
News

FDA grants fast-track designation for Istesso’s IPF candidate

The therapy has reduced inflammation and supported the remodelling of damaged bone. Istesso – a London-based immunometabolism drug development company – has announced that the …

Continue Reading →
News

Valneva and Pfizer report Lyme disease antibody data

Children and adults have been treated using the Lyme disease antibody candidate VLA15 Pfizer has reported antibody persistence data six months after the completion of …

Continue Reading →
News

Merck KGaA’s arpraziquantel validated by European Medicines Agency

Positive scientific opinion by EMA would create a pathway for arpraziquantel in African endemic countries. Merck KGaA (Merck) – known as EMD Serono in the …

Continue Reading →
News

Almirall Joins Project to Allow Study Participants to Use Trial Data

The project involves 27 partners including patient associations, hospitals and universities. Almirall – a company focused on skin health – is participating in Facilitate, a …

Continue Reading →
News

C4XD Signs NRF2 Activator Deal with Astrazeneca

C4XD will receive milestone payments worth up to $16m ahead of the first clinical trial. C4XD – a company focused on drug discovery – has …

Continue Reading →
News

Bristol Myers Squibb Immunotherapy-Chemo Combination Gets NICE Recommendation

Treatment involves adults with certain forms of advanced stomach and oesophageal cancer. Bristol Myers Squibb (BMS) has announced that the National Institute for Health and …

Continue Reading →